𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Milk protein-derived opioid receptor ligands

✍ Scribed by Hansjörg Teschemacher; Gertrud Koch; Victor Brantl


Publisher
Wiley (John Wiley & Sons)
Year
1997
Tongue
English
Weight
143 KB
Volume
43
Category
Article
ISSN
0006-3525

No coin nor oath required. For personal study only.

✦ Synopsis


Milk is a mammalian characteristic and is of particular importance for humans: Mother's milk or its substitutes from cows' milk are absolutely essential nutriments for the neonate and cows' milk also represents a basic foodstuff for adults.

However, in addition to their well-known nutritive role, milk constituents apparently are also able to carry specific information from the milk producer's to the milk receiver's organism: Thus, a number of milk protein fragments has been shown to behave like opioid receptor ligands able to address opioidergic systems in the adult's or in the neonate's organism.

With respect to the proteins, which they are derived off, these peptides have been named a-casein exorphins or casoxin D (a-casein), b-casomorphins or b-casorphin (b-casein), casoxin or casoxin A, B, or C (k-casein), a-lactorphins (a-lactalbumin), b-lactorphin (blactoglobulin) or lactoferroxins (lactoferrin). Only casoxins and lactoferroxins display antagonistic properties; the other peptides behave like opioid receptor agonists.

Most of the information available so far has been collected about b-casomorphins. These peptides obviously can be released from b-casein in the adult's or in the neonate's organism, where they might elicit opioid effects in the frame of a regulatory role as ''food hormones''. Several synthetic b-casomorphin derivatives have been shown to be highly specific and potent m-type opioid receptor ligands which frequently have been used as standard tools in opioid research.


📜 SIMILAR VOLUMES


Complementarity of δ opioid ligand pharm
✍ Henry I. Mosberg 📂 Article 📅 1999 🏛 Wiley (John Wiley & Sons) 🌐 English ⚖ 426 KB 👁 1 views

The elaboration of a pharmacophore model for the ␦ opioid receptor selective ligand JOM-13 (Tyr-c[D-Cys-Phe-D-Pen]OH) and the parallel, independent development of a structural model of the ␦ receptor are summarized. Although the backbone conformation of JOM-13's tripeptide cycle is well defined, con